VIDEO: AMD highlights from ARVO 2021

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There were a variety of really great highlights from ARVO. Some really important studies that came out this year. The first was around AREDS Two the age-related eye disease studies. The second phase, which reported ten-year data, again very supportive of vitamin therapy for the treatment of non exited AMD in the prevention of progressing to exited macular degeneration. The second important study I think was around geographic atrophy and in particular a product called APL two which is currently in its phase trials. And we have some important data coming out soon enough about the phase three study. And we saw some interesting sub studies to this data was showing you that the product, which is the complement factor inhibitor prevents the progression of patients with incomplete loss of the, or the retina in places. So even before geographic atrophy sets in it has a good effect on preventing the progression of those incomplete areas which I think was very, very important. And the last of the studies really focused on what macular degeneration and two different things. And the first was Novartis and the product was just , reporting data on the side effect profile of their drug B O view or in practice right now. And what it showed was again a replication of the retinal vasculitis retinal vascular occlusive disease and potentially the vision loss associated with this ca... this drug in real practice due to its side effect profile, and the latter studies focused on extended durability that we're hoping to see with some sustained delivery models including the port delivery system, as well as gene therapy which are two really huge advents for potentially improving the durability of our treatments for our patients with wet macular degeneration.